Northwest Biotherapeutics
Northwest Biotherapeutics is an American pharmaceutical company that focuses on developing immunotherapies against different types of cancer.
Mission
NWBT's stated goals stress product quality and purity, innovation, and efficient production.[1]
Technology
The DCVax® technology upon which NWBT's therapies rely involves injecting cancer patients with dendritic cells, which contain high levels of the same antigens found in tumor cells. The immune system, alerted by these antigens, attacks the cancer as well as the injected cells.
Products
DCVax® Brain, the first vaccine against brain cancer approved by the American Food and Drug Administration (FDA), is set to be distributed at select centers in Switzerland by September 2007.[1] DCVax® Prostate has also been approved by the FDA for trials.[2]
Footnotes and references
- ↑ "First brain cancer vaccine approved in Switzerland". Yahoo! News. 2007-07-09. Retrieved 2007-07-09. Check date values in:
|date=(help)
External links
[Northwest Biotherapeutics homepage | http://www.nwbio.com/about_overview.php]
NWBT Template:NASDAQ